DOCSLIB.ORG

Sarcoidosis Treatment Guidelines

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sarcoidosis Treatment Guidelines SARCOIDOSIS TREATMENT GUIDELINES INTRODUCTION Goals of Sarcoidosis Management Sarcoidosis is a chronic inflammatory granulomatous dis- The goals of sarcoidosis management are to prevent or con- ease that primarily affects the lungs, although multi-organ trol organ damage, relieve symptoms and improve the involvement is common. The etiology of sarcoidosis is not patient’s quality of life. An evaluation by a pulmonologist is clear; however, genetic and environmental factors probably strongly recommended. For patients with extrapulmonary play a role in the development and expression of the disease. involvement, a multidisciplinary approach may be required. A patient may need to see an ophthalmologist for ocular dis- Once thought to be rare, sarcoidosis affects people ease, a cardiologist for cardiac disease, a neurologist for neu- throughout the world. It can affect people of any age, race, rological disease, a nephrologist for renal disease, and so or gender; however, the prevalence is highest among adults forth. between the ages of 20 and 40 and in African Americans and people of European – particularly Scandinavian – descent. Pharmacologic Treatment Symptoms and severity can vary by race and gender, with While a significant percentage of sarcoidosis patients never African Americans being more severely affected than need therapy, there are several groups which require treat- Caucasians. Extrapulmonary sarcoidosis is common in cer- ment. In this monograph, we will discuss several of the com- tain populations, for example: chronic uveitis in African monly used drugs for sarcoidosis and their potential toxici- Americans, painful skin lesions in Northern Europeans and ties, and will provide algorithms for use of these drugs to cardiac and ocular involvement in Japanese. treat the symptoms associated with specific organ involve- ment. 1 Corticosteroids Methotrexate. Methotrexate is one of the most commonly used corticosteroid-sparing therapies for sarcoidosis, due to Corticosteroid medications are considered the first line of its effectiveness, low cost and, at the dosages used to treat treatment for sarcoidosis that requires therapy. Oral corti- sarcoidosis, relatively low risk of side effects compared to costeroids effectively reduce systemic inflammation in most other cytotoxic agents. The drug can be given orally or sub- people, thereby slowing, stopping or even preventing organ cutaneously. Due to the potential for hepatic and hematolog- damage. Corticosteroids may be prescribed alone or with ic toxicity, regular monitoring is required. Since the drug is other medications. Although there is no standard dosage or cleared by the kidneys, one should also monitor renal func- duration of corticosteroid therapy, the charts in this mono- tion. Dosage adjustment may be needed or an alternative graph will provide guidelines for individual organ involve- corticosteroid-sparing drug may be considered in those with ment. It is recommended that patients on corticosteroids renal insufficiency, e.g. serum creatinine > 1.5 (gfr < 50 long term be monitored for osteoporosis and treated appro- ml/min). It is recommended that patients have a CBC and priately. hepatic and renal function every 1-3 months. Folic acid sup- Topical corticosteroids or intralesional injections may be plementation may be prescribed to reduce toxicity. prescribed for cutaneous involvement, and eye drops may be Azathioprine. What little research has been done on the prescribed for uveitis. Corticosteroid inhalers may be useful subject shows that azathioprine (Imuran®) is roughly as in those with evidence of bronchial hyperactivity. effective as methotrexate in treating sarcoidosis. It is consid- Hydroxychloroquine. As a treatment for sarcoidosis, the ered when there is a contraindication to methothrexate, such antimalarial drug hydroxychloroquine (Plaquenil®) is most as renal or hepatic function impairment. The side effects of likely to be effective in patients with dermatologic involve- azathioprine include dyspepsia, oral ulcers, myalgia, malaise, ment, joint manifestations and hypercalcemia. Due to poten- jaundice and blurred vision. Compared to methotrexate, tial macular toxicity, it is recommended that patients on there is also evidence of a higher frequency of opportunistic hydroxychloroquine have an eye examination every 6-12 infections and possibly malignancy with azathioprine use. months. Some clinicians measure thiopurine S-methyltransferase (TPMT) levels prior to the first dose to determine if patients 2 have TPMT deficiency and therefore are at increased risk should be considered as an alternative for patients who can- for toxicity. Others measure the CBC 2-4 weeks after the not tolerate methotrexate. It is recommended for the first first dosage. It is recommended that patients taking azathio- three months of therapy patients have monthly CBCs. For prine have a CBC and hepatic and renal function tests at patients who experience severe toxicity from leflunomide, least every 1-3 three months. cholestyramine therapy may be useful. Mycophenolate mofetil. First developed to prevent organ Cyclophosphamide. Due to its toxicity, cyclophosphamide transplant rejection, mycophenolate mofetil (CellCept®) is (Cytoxan ®, Endoxan®) is usually reserved for severe dis- prescribed for a number of autoimmune and inflammatory ease not controlled by methotrexate or azathioprine. Case diseases, including rheumatoid arthritis and lupus nephritis. studies suggest that cyclophosphamide is effective for some Anecdotal reports have shown it to be effective in treating people and is perhaps particularly useful in severe disabling sarcoidosis. The principal adverse reactions associated with neurosarcoidosis that has not responded to other therapies, the administration of mycophenolate mofetil include diar- including intravenous corticosteroids and anti-TNF therapy. rhea, leukopenia, sepsis and vomiting. Compared to azathio- Its side effects can include nausea, vomiting, anorexia, prine, there is also evidence of a higher frequency of oppor- alopecia, acne, leukopenia, oral ulcers, skin hyperpigmenta- tunistic infections and malignancy. It is recommended that tion and fatigue. Less common but more severe side effects patients taking mycophenolate have a CBC and hepatic and include hemorrhagic cystitis and an increased risk for cancer. renal function tests at least every 3 months. Overall, less toxicity has been reported with intermittent Leflunomide. Leflunomide (Arava®) is a cytotoxic drug intravenous administration compared to daily oral use of that has been used as a single agent or in combination with cyclophosphamide. As with other immunosuppressants, methotrexate for the treatment of rheumatoid arthritis. In monitoring should include CBC and hepatic and renal func- sarcoidosis, the most common indications for therapy are tion tests every 1-3 months. Due to the risk of bladder can- ocular and lung disease. Although experience is limited, it cer, urinalysis is needed every month. 3 Infliximab. An infused TNF inhibitor, infliximab Adalimumab. The TNF inhibitor adalimumab (Humira®), (Remicade®) has been approved for several inflammatory given by subcutaneous injection, has been approved for diseases including rheumatoid arthritis and Crohn’s disease. rheumatoid arthritis and several other forms of arthritis. Small, short-term studies have shown infliximab to be effec- Anecdotal reports have shown adalimumab to be effective in tive in reducing sarcoidosis symptoms in patients who did reducing sarcoidosis symptoms. Adalimumab can cause a not respond to other treatments. Infliximab can cause a vari- variety of side effects, including abdominal pain, nausea, ety of side effects, including abdominal pain, nausea, diar- diarrhea, dyspepsia, headache, rash, pruritus, pharyngitis rhea, dyspepsia, headache, rash, pruritus, pharyngitis and and sinusitis, and sore throat. Local injection site reactions sinusitis, and sore throat. Infusion reactions, including have been reported. Adalimumab also increases the risk of severe anaphylaxis, can occur. Infliximab also increases the infection and certain types of cancer, autoimmune disease risk of infection and certain types of cancer, autoimmune dis- and demyelinating disease. Adalimumab should be consid- ease and demyelinating disease. It is recommended that ered for patients who have been treated successfully with patients have a PPD for tuberculosis prior to beginning ther- infliximab but have developed antibodies. It is recommend- apy and that infliximab be withheld in the event of active ed that patients have a PPD for tuberculosis prior to begin- infection. ning therapy and that adalimumab be withheld in the event of active infection. 4 STANDARD THERAPIES STANDARD THERAPIES DRUG DOSAGE MAJOR TOXICITY MONITORING Blood pressure, weight, glucose if Diabetes, hypertension, weight gain, Prednisone 5-40mg daily clinically indicated. Osteoporosis and cataracts, glaucoma bone density checks Hydroxychloroquine 200-400mg daily Ocular, hepatic, cutaneous Eye examination every 6-12 months CBC, hepatic and renal function Methotrexate 5-20mg weekly Hematologic, hepatotoxic, pulmonary every 1-3 months CBC, hepatic and renal function Azathioprine* 50-200mg daily Hematologic, gastrointestional every 1-3 months CBC, hepatic and renal function Leflunomide* 10-20mg daily Hematologic, hepatotoxic every 1-3 months CBC, hepatic and renal function Mycophenylate 500-1500mg twice daily Hematologic, gastrointestional every 1-3 months Allergic reactions, increased risk
Load more

Recommended publications
  • Practice Guideline: Disease-Modifying Therapies for Adults with Multiple Sclerosis
    Practice guideline: Disease-modifying therapies for adults with multiple sclerosis Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology Alexander Rae-Grant, MD1; Gregory S. Day, MD, MSc2; Ruth Ann Marrie, MD, PhD3; Alejandro Rabinstein, MD4; Bruce A.C. Cree, MD, PhD, MAS5; Gary S. Gronseth, MD6; Michael Haboubi, DO7; June Halper, MSN, APN-C, MSCN8; Jonathan P. Hosey, MD9; David E. Jones, MD10; Robert Lisak, MD11; Daniel Pelletier, MD12; Sonja Potrebic, MD, PhD13; Cynthia Sitcov14; Rick Sommers, LMSW15; Julie Stachowiak, PhD16; Thomas S.D. Getchius17; Shannon A. Merillat, MLIS18; Tamara Pringsheim, MD, MSc19 1. Department of Neurology, Cleveland Clinic, OH 2. Department of Neurology, Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University in St. Louis, MO 3. Departments of Medicine and Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada 4. Department of Neurology, Mayo Clinic, Rochester, MN 5. UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco 6. Department of Neurology, Kansas University Medical Center, Kansas City 7. Department of Neurology, School of Medicine, University of Louisville, KY 8. Consortium of Multiple Sclerosis Centers, Hackensack, NJ 9. Department of Neuroscience, St. Luke’s University Health Network, Bethlehem, PA 10. Department of Neurology, School of Medicine, University of Virginia, Charlottesville 11. Consortium of Multiple Sclerosis Centers, Hackensack, NJ, and Department of Neurology, School of Medicine, Wayne State University, Detroit, MI 12. Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles 13. Neurology Department, Southern California Permanente Medical Group, Kaiser, Los Angeles 14.
    [Show full text]
  • Consequences of Sarcoidosis
    Consequences of Sarcoidosis Marjolein Drent, MD, PhDa,b,c,*, Bert Strookappe, MScc,d, Elske Hoitsma, MD, PhDc,e, Jolanda De Vries, MSc, PhDc,f,g KEYWORDS Cognitive impairment Depressive symptoms Exercise limitation Fatigue Pain Rehabilitation Sarcoidosis Small fiber neuropathy Quality of life KEY POINTS Consequences of sarcoidosis are wide ranging, and have a great impact on patients’ lives. Sarcoidosis patients suffer not only from organ-related symptoms, but also from a wide spectrum of rather nonspecific disabling symptoms. Absence of evidence does not mean evidence of absence. Management of sarcoidosis requires a multidisciplinary personalized approach that focuses on somatic as well as psychosocial aspects of the disease. INTRODUCTION of sarcoidosis patients include symptoms that cannot be explained by granulomatous involve- The clinical expression, natural history, and prog- ment of a particular organ.4 Apart from lung- nosis of sarcoidosis are highly variable and its related symptoms (eg, coughing, breathlessness, course is often unpredictable.1 Clinical manifesta- 1,2 and dyspnea on exertion), patients may suffer tions vary with the organs involved. The lungs from a wide range of rather nonspecific disabling are affected in approximately 90% of patients symptoms.2,5 These symptoms, such as fatigue, with sarcoidosis, and the disease frequently also fever, anorexia, arthralgia, muscle pain, general involves the lymph nodes, skin, and eyes. Remis- weakness, muscle weakness, exercise limitation, sion occurs in more than one-half of patients within and cognitive failure, often do not correspond 3 years of diagnosis, and within 10 years in two- 2,5–9 2 with objective physical evidence of disease. thirds, with few or no remaining consequences.
    [Show full text]
  • An Elderly Patient with Sarcoidosis Manifesting Panhypopituitarism with Central Diabetes Insipidus
    Endocrine Journal 2007, 54 (3), 425–430 An Elderly Patient with Sarcoidosis Manifesting Panhypopituitarism with Central Diabetes Insipidus TOMOKO MIYOSHI, FUMIO OTSUKA, MASAYA TAKEDA, KENICHI INAGAKI, HIROYUKI OTANI, TOSHIO OGURA, KEN ICHIKI*, TETSUKI AMANO* AND HIROFUMI MAKINO Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama City, 700-8558, Japan *Aioi City Hospital, 5-12 Sakae-cho, Aioi City, 678-0008, Japan Abstract. We here report a 77-year-old Japanese male who suffered general fatigue with progressive thirst and polyuria. Central diabetes insipidus was diagnosed by depletion of vasopressin secretion in response to increases in serum osmolality. Secretory responses of anterior pituitary hormones including adrenocorticotropin, thyrotropin, gonadotropins and growth hormone were severely impaired. Diffuse swelling of the infundibulum as well as lack of T1-hyperintense signal in the posterior lobe was noted by pituitary magnetic resonance imaging. The presence of bilateral hilar lymphade- nopathy and increased CD4/CD8 ratio in bronchoalveolar lavage fluid was diagnostic for lung sarcoidosis. Physiological doses of corticosteroid and thyroid hormone were administered in addition to desmopressin supplementation. Complete regression of the neurohypophysial swelling was notable two years after corticosteroid replacement. Diffuse damage of anterior pituitary combined with hypothalamic involvement leading to central diabetes insipidus is a rare manifestation in such elderly patients with neurosarcoidosis. Key words: Central diabetes insipidus, Hypophysitis, Lymphocytic infundibuloneurohypophysitis, Neurosarcoidosis, Panhypopituitarism, Sarcoidosis (Endocrine Journal 54: 425–430, 2007) SARCOIDOSIS is a systemic granulomatous disease dysfunction and less frequently involve the infundibu- involving multiple organs, in which endocrinopathy is lum and/or the pituitary gland, leading to hypothalamic rarely complicated [1].
    [Show full text]
  • Leflunomide Affect Fertility Or Pregnancy?
    Does Leflunomide affect fertility or pregnancy? Leflunomide may cause serious birth defects. Do not take Leflunomide if you are planning to conceive, during pregnancy or when breastfeeding. It is necessary for men and women to use contraception while on National University Hospital Leflunomide.. The drug may remain in the body for up to two years after the last dose. Women Medication Information must not become pregnant and men must not 5 Lower Kent Ridge Road, Singapore 119074 for Patients father children within two years of stopping Website: www.nuh.com.sg Leflunomide; unless medicine is given to get rid LEFLUNOMIDE of it from your body system (consult your doctor). Company Registration No. 198500843R You must not take Leflunomide unless you are on reliable contraception. Pharmacy (Main Building): 6772 5181/5182 Can I have immunisations while on Pharmacy (Kent Ridge Wing): 6772 5184 Leflunomide? Pharmacy (NUH Medical Centre): 6772 8205 Pneumococcal, influenza, hepatitis A and B, tetanus vaccinations are allowed. Avoid immunisations with live vaccines such as polio, varicella (chicken pox), measles, mumps and rubella (MMR). The information provided in this publication is meant purely for educational purposes and may not be used as a substitute for medical diagnosis or treatment. You should seek the advice of your doctor or a qualified healthcare provider before starting any treatment or if you have any questions related to your health, physical fitness or medical conditions. Information is correct at time of printing and subject to revision without prior Are there any alternatives to Leflunomide? notice. Copyright 2014.NationalUniversityHospital Your doctor will advise on the safest and most All Rights reserved.
    [Show full text]
  • Systematic Review of Immunomodulatory Drugs for the Treatment of People with Multiple Sclerosis: Is There Good Quality Evidence on Evectiveness and Cost?
    574 J Neurol Neurosurg Psychiatry 2001;70:574–579 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.70.5.574 on 1 May 2001. Downloaded from Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on eVectiveness and cost? J Bryant, A Clegg, R Milne Abstract clinical and cost eVectiveness of health technolo- Objective—To review the clinical eVec- gies and provide guidance to the NHS. At the tiveness and costs of a range of disease time of writing, it is considering â-interferon and modifying drugs in multiple sclerosis. glatiramer in the treatment of multiple sclerosis. Drugs included are azathioprine, cladrib- Excluded from the NICE appraisal are several ine, cyclophosphamide, intravenous im- other disease modifying drugs that may be used munoglobulin, methotrexate, and in the treatment of this disease. A comprehen- mitoxantrone. sive appraisal of disease modifying drugs for the Methods—Electronic databases and bibli- treatment of multiple sclerosis should consider ographies of related papers were searched all competing alternatives. for randomised controlled trials (RCTs) This study is, to the best of our knowledge, the first systematic review of a range of disease and systematic reviews, and experts and modifying drugs for multiple sclerosis. We were pharmaceutical companies were con- commissioned by the NHS Research and tacted for further information. Inclusion Development Health Technology Assessment and quality criteria were assessed, data (HTA) programme to undertake a rapid system- extraction undertaken by one reviewer atic review to appraise the evidence on the eVec- and checked by a second reviewer, with tiveness and cost of azathioprine, cladribine, discrepancies being resolved through dis- cyclophosphamide, intravenous immunoglobu- cussion.
    [Show full text]
  • Coexistence of Neurosarcoidosis and Multiple Sclerosis
    Neurol. Croat. Vol. 61, 3-4, 2012 Coexistence of neurosarcoidosis and multiple sclerosis L. Radolović Prenc1, S.Telarović2,3, I.Vidović1, J. Sepčić4, L. Labinac Peteh1 ABSTRACT - Sarcoidosis is a multisystem infl ammatory disease of unknown etiology that predominantly aff ects the lungs and intrathoracic lymph nodes, but in 6% of cases it also occurs in central or peripheral nervous system. Multiple sclerosis (MS) is an immune-mediated infl ammatory disease that attacks myeli- nated axons in the central nervous system. Coexistence of sarcoidosis and other autoimmune diseases like MS is rarely reported in the literature. We present a case report of a patient with coexisting sarcoidosis and 67 MS, with a positive family history of MS. Symptoms of sarcoidosis appeared three years before the onset of Number 3-4, 2012 Number symptoms typical for MS. Similarity of demyelinating lesions in the nervous system, increased IgG in cere- brospinal fl uid and good response to corticosteroid treatment point to similar etiology. Th e onset of diseases like sarcoidosis and MS in the same patient over a period of only a few years opens the question whether the two separate entities come in sequence or the onset of sarcoidosis occurs during development of typical clinical presentation of MS. Key words: sarcoidosis, encephalomyelitis, multiple sclerosis INTRODUCTION lymph nodes (Figs. 1 and 2), or pathologic skin nodes or bone cysts, especially in hands, and posi- Sarcoidosis is an infl ammatory disorder of un- tive Kveim test (2). Cerebrospinal fl uid (CSF) anal- known origin, characterized by epithelioid cell ysis shows increased IgG, pleocytosis with protein- granulomas in various organs (1).
    [Show full text]
  • Neurosarcoidosis
    CHAPTER 11 Neurosarcoidosis E. Hoitsma*,#, O.P. Sharma} *Dept of Neurology and #Sarcoidosis Management Centre, University Hospital Maastricht, Maastricht, The Netherlands, and }Dept of Pulmonary and Critical Care Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. Correspondence: O.P. Sharma, Room 11-900, LACzUSC Medical Center, 1200 North State Street, Los Angeles, CA 90033, USA. Fax: 1 3232262728; E-mail: [email protected] Sarcoidosis is an inflammatory multisystemic disorder. Its cause is not known. The disease may involve any part of the nervous system. The incidence of clinical involvement of the nervous system in a sarcoidosis population is estimated to be y5–15% [1, 2]. However, the incidence of subclinical neurosarcoidosis may be much higher [3, 4]. Necropsy studies suggest that ante mortem diagnosis is made in only 50% of patients with nervous system involvement [5]. As neurosarcoidosis may manifest itself in many different ways, diagnosis may be complicated [2, 3, 6–10]. It may appear in an acute explosive fashion or as a slow chronic illness. Furthermore, any part of the nervous system can be attacked by sarcoidosis, but the cranial nerves, hypothalamus and pituitary gland are more commonly involved [1]. Sarcoid granulomas can affect the meninges, parenchyma of the brain, hypothalamus, brainstem, subependymal layer of the ventricular system, choroid plexuses and peripheral nerves, and also the blood vessels supplying the nervous structures [11, 12]. One-third of neurosarcoidosis patients show multiple neurological lesions. If neurological syndromes develop in a patient with biopsy- proven active systemic sarcoidosis, the diagnosis is usually easy. However, without biopsy evidence of sarcoidosis at other sites, nervous system sarcoidosis remains a difficult diagnosis [13].
    [Show full text]
  • Imuran Data Sheet
    NEW ZEALAND DATA SHEET 1. IMURAN 25mg, 50mg Imuran tablets (azathioprine 25mg, 50mg) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 25mg, 50 mg azathioprine BP. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM 25mg: Orange tablet, film coated, round, biconvex, unscored, branded IM2. 50mg: Yellow tablet, film coated, round biconvex, scored, branded IM5. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications IMURAN is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. Therapeutic effect may be evident only after weeks or months and can include a steroid- sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. IMURAN, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated to enhance the survival of organ transplants, such as renal transplants, cardiac transplants, and hepatic transplants; and to reduce the corticosteroid requirements of renal transplant recipients. IMURAN is indicated for the treatment of moderate to severe Crohn’s disease in patients in whom corticosteroid therapy is required, in patients who cannot tolerate corticosteroid therapy, or in patients whose disease is refractory to other standard first line therapy. IMURAN, either alone or more usually in combination with corticosteroids and/or other medicines and procedures, has been used with clinical benefit (which may include reduction of dosage or discontinuation of corticosteroids) in a proportion of patients suffering from the following: • severe rheumatoid arthritis; • systemic lupus erythematosus; • dermatomyositis and polymyositis; • auto-immune chronic active hepatitis; • pemphigus vulgaris; • polyarteritis nodosa; • auto-immune haemolytic anaemia; • chronic refractory idiopathic thrombocytopenic purpura; • ulcerative colitis.
    [Show full text]
  • Azathioprine As a Steroid Sparing Agent in Leprosy Type 2 Reactions: Report of Nine Cases
    Lepr Rev (2011) 82, 304–309 CASE REPORT Azathioprine as a steroid sparing agent in leprosy Type 2 reactions: Report of nine cases SANDRA MARIA BARBOSA DURA˜ ES*, SIMONE DE ABREU NEVES SALLES**, VERONICA RODRIGUES BOGADO LEITE*** & MORGANA OHIRA GAZZETA**** *Adjunct Professor of Dermatology at Universidade Federal Fluminense, Rio de Janeiro, Brazil **Assistant Professor of Dermatology at Universidade Federal Fluminense, Rio de Janeiro, Brazil ***Graduate Student in Dermatology, Universidade Federal Fluminense, Rio de Janeiro, Brazil ****Medical student at Universidade Federal Fluminense, Rio de Janeiro, Brazil Accepted for publication 06 April 2011 Introduction Glucocorticosteroids (GCS) are the main therapeutic agent used to treat leprosy reactions. Some patients have prolonged reactions and require prolonged therapy with GCS.1,2 Corticosteroid-sparing agents have been used especially in patients with rheumatological diseases to reduce the GCS doses required to control the disease, or as an alternative to GCS, and to reduce side effects. The literature contains few experiences in the use of such GCS sparing agents in leprosy reactions. After methotrexate (whose use is widespread in psoriasis), azathioprine is the immunosuppressant most widely used by dermatologists because of its immunosuppressive effect, which is superior to methotrexate, has less serious side effects than cyclosporine, and a lower cost than that of mycophenolate, tracolimus and sirolimus. These factors guided our predilection for the use of azathioprine over other immunosuppressants since we started using it in 1996, yet there was no publication about its use in leprosy reactions. From 2003 onwards articles began to emerge on the use of azathioprine in leprosy reactions. In the treatment of Type 1 reactions, when followed by prednisolone, it has been found to provide results comparable to those with prednisolone alone,3 thus possibly Correspondence to: Sandra Maria Barbosa Dura˜es, Hospital Universita´rio Antonio Pedro–Universidade Federal Fluminense, Av.
    [Show full text]
  • Immunomodulators
    Fact Sheet News from the IBD Help Center IMMUNOMODULATORS Medical treatment for Crohn’s disease and ulcerative colitis has two main goals: achieving remission (control or resolution of inflammation leading to symptom resolution with healing of the inflamed tissue) and then maintaining remission. To accomplish these goals, treatment is aimed at controlling the ongoing inflammation in the intestine—the cause of inflammatory bowel disease (IBD) symptoms. As the name implies, immunomodulators modify the activity of the immune system, in turn, decreasing the inflammatory response. Immunomodulators are most often used in organ transplantation to prevent rejection of the new organ as well as in autoimmune diseases such as rheumatoid arthritis. Since the late 1960s, they have also been used to treat people with IBD, where the normal regulation of the immune system is affected. Immunomodulators, by themselves or with another agent, may be appropriate in the following treatment situations: • Nonresponse or intolerance to aminosalicylates, antibiotics, or corticosteroids • Steroid-dependent disease or frequent need for steroids • Perianal (around the anus) disease that does not respond to antibiotics • Fistulas (abnormal channels between two loops of intestine, or between the intestine and another structure—such as the skin) • To bolster or optimize the effect of a biologic drug and prevent the development of resistance to biologic drugs • To prevent recurrence after surgery Because it can take up to three to six months to see an improvement in symptoms with immunomodulators, steroids may be started at the same time to produce a faster response. Lower doses of the steroid may be utilized in some cases, producing fewer side effects.
    [Show full text]
  • Azathioprine (PDF, 34KB)
    Oxford Children’s Hospital Paediatric Gastroenterology Department Azathioprine Information for patients and parents Medicines Information This information leaflet answers common questions parents and patients ask about their medicine. Further information can be found in the information leaflet supplied by the manufacturer, or ask your pharmacist or doctor. page 2 Why have I been started on this medicine? Azathioprine (also known as Imuran®) is often prescribed for patients with chronic active inflammatory bowel disease that requires continuous or repeated courses of corticosteroids. Azathioprine is often referred to as a “steroid sparing agent” or “immunomodulator”. It allows the dose of steroids to be kept to a minimum and eventually stop. Azathioprine is also used in other groups of patients including those with organ transplants, rheumatoid arthritis and psoriasis. How does it work? Azathioprine suppresses inflammation and ‘turns-off’ the activity of the immune system (hence the term “immunomodulator”). Evidence for its effectiveness is stronger in Crohn’s disease but it is widely used in ulcerative colitis. How long does it take to work? Azathioprine acts slowly and can take several weeks to take effect. What dose do I take? The dose of azathioprine is based on weight in children and is around 1-2 mg/kg, once daily. Occasionally, higher doses may be required. How do I take it? Azathioprine comes in tablet form and is available in two different strengths – 50mg and 25mg. The dose should be taken once a day with, or soon after food (it can cause stomach irritation if taken on an empty stomach). We can also order a special liquid form which is 25mg/5ml, but it may take a few days to come in.
    [Show full text]
  • Azathioprine (In Conjunction with Prednisolone) ESCA: for the Treatment of Interstitial Lung Disease AREAS of RESPONSIBILITY for the SHARING of CARE
    Effective Shared Care Agreement (ESCA) Azathioprine (in conjunction with prednisolone) ESCA: For the treatment of Interstitial lung disease AREAS OF RESPONSIBILITY FOR THE SHARING OF CARE This shared care agreement outlines suggested ways in which the responsibilities for managing the prescribing of Azathioprine (in conjunction with prednisolone) for Interstitial lung disease can be shared between the specialist and general practitioner (GP). You are invited to participate however, if you do not feel confident to undertake this role, then you are under no obligation to do so. In such an event, the total clinical responsibility for the patient for the diagnosed condition remains with the specialist. Sharing of care assumes communication between the specialist, GP and patient. The intention to share care will be explained to the patient by the specialist initiating treatment. It is important that patients are consulted about treatment and are in agreement with it. Patients with Interstitial lung disease are usually under regular specialist follow-up, which provides an opportunity to discuss drug therapy. The doctor who prescribes the medication legally assumes clinical responsibility for the drug and the consequences of its use. RESPONSIBILITIES and ROLES Specialist responsibilities 1. Confirm the diagnosis of Interstitial lung disease 2. Discuss the potential benefits, treatment side effects, and possible drug interactions with the patient 3. Ask the GP whether he or she is willing to participate in shared care before initiating therapy so that appropriate follow on prescribing arrangements can be made 4. Do baseline monitoring prior to initiation of Azathioprine (in conjunction with prednisolone) 5. Initiate treatment and stabilise dose of Azathioprine (in conjunction with prednisolone) 6.
    [Show full text]